Insider Selling: Bruker (NASDAQ:BRKR) VP Sells $105,740.00 in Stock

Key Points

• Bruker VP Mark Munch sold 2,000 shares at an average price of $52.87, for total proceeds of $105,740. After the transaction, he retained 134,806 shares worth approximately $7.13 million.
• Bruker shares recently traded at $60.67, near the upper end of their 52-week range of $30.09 to $65.30. The company beat quarterly EPS expectations, reporting $0.49 versus the $0.38 consensus, while revenue rose 5.2% year over year.
• Analyst sentiment is mixed, with an overall “Hold” rating and an average price target of $57.00. Bruker also declared a quarterly dividend of $0.05 per share, implying a 0.3% annualized yield.

Bruker Corporation (NASDAQ:BRKR - Get Free Report) VP Mark Munch sold 2,000 shares of the firm's stock in a transaction dated Tuesday, September 15th. The shares were sold at an average price of $52.87, for a total value of $105,740.00. Following the completion of the sale, the vice president directly owned 134,806 shares in the company, valued at $7,127,193.22. This trade represents a 1.46% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Bruker Price Performance

NASDAQ BRKR traded up $4.92 during trading on Wednesday, hitting $60.67. 4,105,639 shares of the company's stock were exchanged, compared to its average volume of 2,368,966. The company has a current ratio of 1.85, a quick ratio of 0.92 and a debt-to-equity ratio of 0.76. The company has a market cap of $9.24 billion, a PE ratio of -86.67, a P/E/G ratio of 1.61 and a beta of 1.26. Bruker Corporation has a fifty-two week low of $30.09 and a fifty-two week high of $65.30. The stock's 50 day moving average price is $58.02 and its two-hundred day moving average price is $49.52.

Bruker (NASDAQ:BRKR - Get Free Report) last posted its quarterly earnings results on Tuesday, August 4th. The medical research company reported $0.49 earnings per share for the quarter, beating analysts' consensus estimates of $0.38 by $0.11. The company had revenue of $838.50 million for the quarter, compared to the consensus estimate of $853.57 million. Bruker had a negative net margin of 2.35% and a positive return on equity of 12.47%. The firm's quarterly revenue was up 5.2% compared to the same quarter last year. During the same period last year, the company posted $0.32 EPS. Bruker has set its FY 2026 guidance at 2.100-2.150 EPS. Research analysts expect that Bruker Corporation will post 2.12 EPS for the current year.

Bruker Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, October 7th. Shareholders of record on Monday, September 21st will be paid a dividend of $0.05 per share. This represents a $0.20 dividend on an annualized basis and a dividend yield of 0.3%. The ex-dividend date of this dividend is Monday, September 21st. Bruker's payout ratio is presently -28.57%.

Institutional Trading of Bruker

Several institutional investors have recently modified their holdings of the business. Sequoia Financial Advisors LLC acquired a new stake in Bruker in the second quarter valued at $250,000. Tidal Investments LLC grew its position in shares of Bruker by 180.4% in the 2nd quarter. Tidal Investments LLC now owns 29,092 shares of the medical research company's stock valued at $1,751,000 after buying an additional 18,715 shares during the last quarter. WINTON GROUP Ltd bought a new stake in shares of Bruker in the 2nd quarter valued at about $344,000. Engineers Gate Manager LP increased its stake in shares of Bruker by 141.8% in the second quarter. Engineers Gate Manager LP now owns 56,825 shares of the medical research company's stock valued at $3,420,000 after buying an additional 33,329 shares during the period. Finally, Integrated Wealth Concepts LLC acquired a new stake in shares of Bruker in the second quarter valued at about $445,000. Institutional investors own 79.52% of the company's stock.

Analysts Set New Price Targets

Several research firms recently weighed in on BRKR. JPMorgan Chase & Co. raised their price objective on Bruker from $55.00 to $65.00 and gave the company an "overweight" rating in a report on Monday, June 8th. Citigroup lowered their target price on Bruker from $60.00 to $53.00 and set a "hold" rating for the company in a report on Wednesday, August 5th. Leerink Partners increased their target price on Bruker from $60.00 to $70.00 and gave the company an "outperform" rating in a research report on Tuesday, July 7th. Zacks Research lowered Bruker from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, September 2nd. Finally, Weiss Ratings restated a "sell (d+)" rating on shares of Bruker in a report on Monday, August 31st. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, five have issued a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of "Hold" and an average target price of $57.00.

About Bruker

Bruker Corporation develops and manufactures scientific instruments, analytical systems and software used to study the chemical, physical and biological properties of materials. Its customers include universities, pharmaceutical and biotechnology companies, industrial manufacturers, hospitals, government laboratories and other research organizations.

The company's product portfolio includes nuclear magnetic resonance and electron paramagnetic resonance systems, mass spectrometers, X-ray analysis instruments, optical and molecular spectroscopy systems, microscopy and nanoanalysis tools, and instruments for microbiology and spatial biology.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.